Illumina said on Tuesday that it has invested an undisclosed amount in Time Boost Capital, a genomics venture fund that plans to match funding raised by startups participating in the UK-based version of Illumina's accelerator program.

Memorial Hermann Health System to launch a new population health program targeting 100,000 individuals.

Since Beckman Coulter began to develop in China more than 40 years ago, it has continued to increase local investment, firmly helped China's laboratory medicine, realized the localization of a number of products, and is committed to promoting leading science and technology to more people.

BforCure, a Paris-based point-of-care diagnostics firm, said on Monday it has received the CE-IVD mark for a PCR kit to detect influenza A, influenza B, and SARS-CoV-2.

Cepheid and BioGX announced on Monday a collaboration to develop a monkeypox assay on the GeneXpert system. Financial and other terms of the deal were not disclosed.

In the past two years, due to the strong cash flow driven by COVID-19, the industrial parks of Chinese IVD enterprises have been ready to land.

Illumina has acquired IDbyDNA, a company developing metagenomic technology for infectious disease testing and pathogen surveillance, GenomeWeb has learned today.

An analysis of monkeypox virus (MPXV) genomes from the ongoing global outbreak has found that the samples cluster together, indicating a single origin for them.

Recently, Shenzhen Eurekabio Technology Co., Ltd. (hereinafter referred to as "Eurekabio") announced that it had completed the 100 million CNY of round B financing.

Israeli diagnostics firm Nucleix said on Wednesday that it has expanded the European Union label indication of its Bladder EpiCheck urothelial cancer test.

Fujirebio announced on Thursday that it is acquiring neurodegenerative disease diagnostic company ADx NeuroSciences for €40 million ($42.1 million).

On May 20, the customs statistical data platform updated the import and export data. The export value of China¡¯s COVID-19 reagents in May was 1.394 billion yuan, which is less than 10% of the value in January.

Illumina (Nasdaq:ILMN) announced today that it launched a new research test, co-developed with Merck (NYSE:MRK).

Belgian molecular diagnostics firm Biocartis said on Wednesday that it will develop a molecular test to identify patients with non-small cell lung cancer most likely to respond to AstraZeneca's Tagrisso (osimertinib) treatment.

On June 22, China IPO learned that Mega Genomics (06667.HK) was officially listed on Hong Kong Exchanges and Clearing Limited today.